Reduce to patients the cost of the drug, Gleevec.
This petition had 426 supporters
Novatis developed this drug in the 1990s. In the years since then the price of the drug has increased astronomically. Novartis must have paid their research costs long ago, but the price just keeps rising. Patients with CML leukemia are dependent on the drug to keep them alive. Our US representatives should work with FDA to pressure Novartis to reduce the cost of Gleevec.
Today: Ruth is counting on you
Ruth Waldhauer needs your help with “Novartis and US Representatives in Congress: Reduce to patients the cost of the drug, Gleevec.”. Join Ruth and 425 supporters today.